Vir Biotechnology, Inc. Stock Price, News & Analysis

Vir Biotechnology has scheduled its first quarter 2025 financial results announcement and corporate update for May 7, 2025. The company will release its Q1 2025 results and corporate updates via press release shortly after market close.

A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on the same day. Stakeholders can access the call through:

• Webcast: Events & Presentations page on Vir's website
• Phone: U.S. toll-free at +1 (888) 800-8770
• International: +1 (646) 307-1953
• Conference ID: 7568777

The recorded version will be available approximately two hours after the event and will remain accessible for 30 days.

Vir Biotechnology (Nasdaq: VIR) announced upcoming presentations at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, featuring key clinical data from their hepatitis programs. The presentations will include:

1. A 24-week subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta, examining the impact of baseline viral parameters and cirrhosis status on treatment responses with tobevibart and elebsiran.

2. 24-week post-treatment follow-up data from the MARCH Phase 2 study, evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa, in chronic hepatitis B patients. Previous end-of-treatment data showed promising rates of hepatitis B surface antigen loss in participants with low baseline HBsAg.

3. In vitro characterization data of elebsiran, an investigational siRNA therapeutic targeting hepatitis B virus.

Brii Biosciences (BRIBY) has provided its full-year 2024 financial results and corporate update, highlighting significant progress in its hepatitis B virus (HBV) functional cure program. The company reported strong cash reserves of US$335.7 million, sufficient to fund operations into 2028.

Key developments include the strategic acquisition of BRII-179's intellectual property for $18 million and advancement of multiple Phase 2b studies. The ENHANCE study completed enrollment in January 2025, while the ENSURE study showed promising 48-week end-of-treatment data, demonstrating higher HBV surface antigen loss rates with elebsiran combination therapy.

Financial results showed a cash position of RMB2,413.4 million, down 9.3% year-over-year. Research and development expenses decreased by 38% to RMB249.8 million, while administrative expenses reduced by 22% to RMB153.2 million. The company reported an increased loss of RMB512.4 million for 2024, up 177.9% from 2023, primarily due to investment-related losses and impairment charges.

Vir Biotechnology (Nasdaq: VIR) has initiated its Phase 3 ECLIPSE registrational program, enrolling the first patient to evaluate the combination of tobevibart and elebsiran for chronic hepatitis delta (CHD) treatment.

The program consists of three trials: ECLIPSE 1 and 2 (Phase 3) for registrational data submission to regulatory agencies, and ECLIPSE 3 (Phase 2b) to support access and reimbursement strategies in European markets. The combination therapy has shown promising results in the SOLSTICE Phase 2 trial, demonstrating ability to reduce hepatitis delta virus to undetectable levels.

CHD, the most severe form of chronic viral hepatitis, typically progresses to cirrhosis and liver failure within 5 years. Currently, there are no approved treatments in the U.S. and options globally. The therapy has received multiple regulatory recognitions, including FDA Breakthrough and Fast Track designations, and EMA Priority Medicines and orphan drug designation.

Vir Biotechnology (VIR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its pipeline programs. The company ended 2024 with $1.10 billion in cash and investments, projecting runway into mid-2027.

Key developments include the upcoming Phase 3 ECLIPSE program for chronic hepatitis delta in H1 2025, with the treatment receiving multiple regulatory designations. Their dual-masked T-cell engagers showed promising results: VIR-5818 demonstrated tumor shrinkage in 50% of participants, while VIR-5500 showed PSA reductions in 100% of prostate cancer patients.

Financial highlights for Q4 2024: Revenue was $12.4 million, R&D expenses were $106.1 million, and net loss was $104.6 million ($0.76 per share). Full-year 2024 showed revenue of $74.2 million and net loss of $522.0 million ($3.83 per share), with a 28% year-over-year reduction in operating expenses.

Vir Biotechnology (Nasdaq: VIR) has announced its executive team's upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts.

The event will be accessible through a live webcast available in the Investors section of Vir Biotechnology's website under Events & Presentations. The recording will remain archived for 30 days following the presentation.

Vir Biotechnology (Nasdaq: VIR) has announced it will provide a corporate update and report its fourth quarter and full year 2024 financial results on February 26, 2025. The announcement will be made after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.

The financial results and corporate update will be accessible through a press release on the company's website's Investors section. Interested parties can join the conference call via webcast or by phone using the U.S. toll-free number +1 (888) 800-8770 or international number +1 (646) 307-1953, with Conference ID: 7568777. A recording will be available approximately two hours after the event and archived for 30 days.

Vir Biotechnology has announced promising Phase 1 data for two dual-masked T-cell engagers: VIR-5818 for HER2-expressing solid tumors and VIR-5500 for metastatic castration-resistant prostate cancer (mCRPC).

For VIR-5818, tumor shrinkage was observed in 50% (10/20) of participants receiving doses ≥400 µg/kg, with confirmed partial responses in 33% (2/6) of HER2-positive colorectal cancer patients. VIR-5500 showed PSA declines in 100% (12/12) of mCRPC patients, with PSA50 response confirmed in 58% (7/12) of patients receiving first doses ≥120 µg/kg.

Both treatments demonstrated promising safety profiles with no dose-limiting cytokine release syndrome (CRS) and maximum tolerated dose not yet reached. The PRO-XTEN™ masking technology showed minimal systemic unmasking, potentially enabling selective activation in tumor microenvironment and reducing toxicity.